Data suggest radium-223 and PSMA-targeted radionuclides are well tolerated in prostate cancer
“We look forward to the optimization of these drugs,” says Scott T. Tagawa, MD, MS, FACP.
In this video, Scott T. Tagawa, MD, MS, FACP, discusses the main points of the presentation, “Therapeutic radiopharmaceuticals: Past, present, and future,” which was given recently at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Tagawa is an associate professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.
PSMA levels linked to tumor biology, treatment sensitivity in treatment-naïve prostate cancer
September 20th 2024“Our findings suggest that high PSMA tumors may respond better to AR-targeting therapies. Tumors with low PSMA possess markers of cancer stem cells and are associated with resistance to radiotherapy," the authors write.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
